Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Begins Phase I Testing of Cancer Drug

Premium

Dicerna Pharmaceuticals this week announced that it has begun dosing patients in a Phase I trial of its RNAi cancer treatment DCR-MYC, formerly known as DCR-M1711.

In the dose-escalating trial, once-weekly infusions of the drug will be administered to up to 66 patients with solid tumors, multiple myeloma, or lymphoma who are refractory or unresponsive to other treatments for three weeks.

Endpoints of the trial include determination of the drug's maximum tolerated dose, as well as its pharmacokinetics, pharmacodynamics, and potential antitumor activity. Data is expected to be available next year.

Dicerna's CSO Bob Brown recently stated that this study will be followed by another Phase I trial in advanced hepatocellular carcinoma patients.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.